/CALT

CALT Stock - Calliditas Therapeutics AB (publ)

Q: What is the analyst price target for CALT?

Analyst price target information is not currently available for CALT.

Q: What is CALT's market cap?

Market capitalization information is not currently available for CALT.

Healthcare|Biotechnology|NASDAQ

$40.00-0.10%

$0.04 (-0.10%) • Sep 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+14.2%upside

Target: $45.68

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CALT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.46

52W High$43.00

52W Low$15.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$1.21B	$802.88M	$229.35M	$874,000	$184.83M
Gross Profit	$1.13B	$787.68M	$229.35M	$874,000	$184.83M
Gross Margin	93.6%	98.1%	100.0%	100.0%	100.0%
Operating Income	$-384,397,000	$-421,942,000	$-524,456,000	$-379,720,000	$-28,019,000
Net Income	$-466,185,000	$-412,268,000	$-509,537,000	$-436,511,000	$-32,578,000
Net Margin	-38.6%	-51.3%	-222.2%	-49944.1%	-17.6%
EPS	$-17.38	$-15.56	$-20.04	$-19.46	$-1.76

Company Overview

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$39

Average Target

↓ 2.5% Downside

Now

$18

Low

$39

Average

$60

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
June 20th 2023	H.C. Wainwright	Initiation	Buy	$60
March 1st 2023	Guggenheim	Initiation	Neutral	$18

Earnings History & Surprises

CALT

Beat Rate

33%

Last 15 quarters

Avg Surprise

-67.5%

EPS vs Estimate

Beats / Misses

5/10

Last 12 quarters

Latest EPS

$-0.58

Q4 2024

EPS Surprise History

Q2 23

No data

Q2 23

-76.3%

$-0.67vs$-0.38

Q3 23

-88.2%

$-0.32vs$-0.17

Q4 23

-87.1%

$-0.58vs$-0.31

Q1 24

+14.3%

$-0.06vs$-0.07

Q2 24

-528.6%

$-0.88vs$-0.14

Q3 24

-60.0%

$-0.16vs$-0.10

Q4 24

-163.6%

$-0.58vs$-0.22

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 11, 2024	$-0.22	$-0.58	-163.6%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.10	$-0.16	-60.0%	✗ MISS
Q2 2024	May 23, 2024	$-0.14	$-0.88	-528.6%	✗ MISS
Q1 2024	Mar 13, 2024	$-0.07	$-0.06	+14.3%	✓ BEAT
Q4 2023	Nov 7, 2023	$-0.31	$-0.58	-87.1%	✗ MISS
Q3 2023	Aug 17, 2023	$-0.17	$-0.32	-88.2%	✗ MISS
Q2 2023	May 16, 2023	$-0.38	$-0.67	-76.3%	✗ MISS
Q2 2023	Apr 26, 2023	—	$-0.01	—	—
Q4 2022	Nov 14, 2022	$-0.92	$-0.03	+96.7%	✓ BEAT
Q3 2022	Aug 18, 2022	$-1.00	$-0.74	+26.0%	✓ BEAT
Q2 2022	May 18, 2022	$-0.47	$-0.85	-80.9%	✗ MISS
Q2 2022	Apr 27, 2022	—	$-0.92	—	—
Q4 2021	Nov 18, 2021	$-0.84	$0.05	+106.0%	✓ BEAT
Q3 2021	Aug 19, 2021	$-0.72	$-0.76	-5.6%	✗ MISS
Q2 2021	May 18, 2021	$-0.40	$-0.60	-50.0%	✗ MISS
Q1 2021	Mar 31, 2021	—	$-0.57	—	—
Q4 2020	Nov 12, 2020	$-0.26	$-0.62	-138.5%	✗ MISS
Q3 2020	Aug 13, 2020	$-0.40	$-0.31	+22.5%	✓ BEAT
Q2 2020	May 14, 2020	—	$-0.19	—	—
Q1 2020	Feb 14, 2020	—	$-0.07	—	—

Frequently Asked Questions about CALT

What is CALT's current stock price?

Calliditas Therapeutics AB (publ) (CALT) is currently trading at $40.00 per share. The stock has moved -0.10% today.

What is the analyst price target for CALT?

The average analyst price target for CALT is $45.67, based on 1 analyst.

What sector is Calliditas Therapeutics AB (publ) in?

Calliditas Therapeutics AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CALT's market cap?

Calliditas Therapeutics AB (publ) has a market capitalization of $2.15 billion, making it a mid-cap company.

Does CALT pay dividends?

No, Calliditas Therapeutics AB (publ) does not currently pay a dividend to shareholders.